Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O75154
UPID:
RFIP3_HUMAN
Alternative names:
Arfophilin-1; EF hands-containing Rab-interacting protein; MU-MB-17.148
Alternative UPACC:
O75154; B0QYI8; B0QYT8; B1AHQ0; B4DEI7; B4DZR6; Q4VXV7; Q7Z5E9; Q9H155; Q9H1G0; Q9NUI0
Background:
Rab11 family-interacting protein 3, known as Arfophilin-1, plays a pivotal role in cellular processes, including endocytic traffic regulation and cytokinesis. It ensures the delivery of recycling endosome membranes to the cleavage furrow and maintains the endosomal recycling compartment's structural integrity. Furthermore, it influences breast cancer cell motility by modulating the actin cytoskeleton and enhances dynein motor complex's processivity through interaction with dynactin.
Therapeutic significance:
Understanding the role of Rab11 family-interacting protein 3 could open doors to potential therapeutic strategies.